Your browser doesn't support javascript.
loading
Trends in sales of antidepressants in Brazil from 2014 to 2020: A time trend analysis with joinpoint regression.
Hoefler, Rogério; Tiguman, Gustavo Magno Baldin; Galvão, Taís Freire; Ribeiro-Vaz, Inês; Silva, Marcus Tolentino.
Afiliação
  • Hoefler R; Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Tiguman GMB; Faculty of Pharmaceutical Sciences, State University of Campinas, Campinas, Sao Paulo, Brazil. Electronic address: gustavo.tiguman@gmail.com.
  • Galvão TF; Faculty of Pharmaceutical Sciences, State University of Campinas, Campinas, Sao Paulo, Brazil.
  • Ribeiro-Vaz I; Porto Pharmacovigilance Centre, Center for Health Technology and Services Research (CINTESIS), Faculty of Medicine, University of Porto, Porto, Portugal.
  • Silva MT; Post-Graduate Program of Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Sao Paulo, Brazil.
J Affect Disord ; 323: 213-218, 2023 02 15.
Article em En | MEDLINE | ID: mdl-36436765
BACKGROUND: This study aimed to investigate the trends in antidepressants sales in Brazil. METHODS: We performed a joinpoint analysis of antidepressants sales in Brazil from 2014 to 2020, recorded in the Brazilian National Controlled Products Management System. The primary outcomes were the defined daily dose per 1000 inhabitants per day (DID) and the market shares for each antidepressant per year. We used joinpoint regression to assess the changes in antidepressant consumption in DID to obtain the average annual percent change (AAPC) and 95 % confidence intervals (95 % CI). Changes in market shares were tested by chi-square trend test (p < 0.05 as significant). RESULTS: From 2014 to 2020, 42,252,989 antidepressant sales were recorded in the system. Antidepressant sales increased from 13.7 to 33.6 DID in the period (AAPC: 15.7; 95 % CI: 13.0-18.4; p < 0.001); the largest increases were observed for serotonin reuptake inhibitors and 'other' antidepressants (including serotonin-norepinephrine reuptake inhibitors), whereas tricyclics remained steady. Escitalopram and sertraline were the most sold drugs. Market share of serotonin reuptake inhibitors decreased, particularly for paroxetine (13.1 % to 6.5 %; p = 0.016), while 'other' antidepressants' market share expanded from 21.9 % to 33.3 % (p = 0.027), especially for desvenlafaxine (2.9 % to 14.3 %; p < 0.001). LIMITATIONS: The dataset does not include antidepressants dispensed in hospitals, public services, and compounding pharmacies, neither their therapeutic indications. CONCLUSION: Sales of antidepressants significantly increased in Brazil from 2014 to 2020, which were mainly driven by higher prescriptions of serotonin reuptake inhibitors and 'other' antidepressants classes. Market share changes seem to be driven by novelty of products.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores Seletivos de Recaptação de Serotonina / Antidepressivos Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: J Affect Disord Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Portugal País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores Seletivos de Recaptação de Serotonina / Antidepressivos Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: J Affect Disord Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Portugal País de publicação: Holanda